Clinical review report: Semaglutide (Ozempic) (Novo Nordisk Canada Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2019, 2019
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus |
|---|---|
| Physical Description: | 1 PDF file (149 pages) illustrations |